GLP1R and type 2 diabetes mellitus: Despite guideline recommendations and consistent evidence of cardiovascular risk reduction (including from the present study), DPP-4i use remains prevalent while the adoption of GLP-1 RAs is suboptimal among people with T2D and ASCVD [29], implying the need for a change in clinical practice.